Efficiency of ultrasensitive prostate-specific antigen assay in diagnosing biochemical failure after radical prostatectomy

Japanese Journal of Clinical Oncology

Volumn 37, Issue 6, 2007, Pages 446-451

  Shimizu, Fumitaka ^a   Tanaka, Shiro ^b   Matsuyama, Yutaka ^b   Tominaga, Takashi ^c   Ohashi, Yasuo ^c   Fujime, Makoto ^a  

^a JUNTENDO UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c MITSUI MEMORIAL HOSPITAL   (Japan)

Author keywords

Computer simulation; Prostate specific antigen; Prostatectomy; Prostatic neoplasms; Recurrence

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BIOCHEMISTRY; COMPUTER PROGRAM; COMPUTER SIMULATION; FOLLOW UP; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; PROSTATECTOMY; SENSITIVITY AND SPECIFICITY; TREATMENT FAILURE; VALIDATION PROCESS;

COMPUTER SIMULATION; EFFICIENCY; FOLLOW-UP STUDIES; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY;

EID: 34547896993     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hym043     Document Type: Article

References (25)

1. Han M, Partin AW, Piantadosi S, Epstein JI, Walsh PC. Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol 2001;166:416-9.
2. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003;169:517-23.
3. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591-7.
4. Freedland SJ, Sutter ME, Dorey F, Aronson WJ. Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology 2003;61:365-9.
5. Stephenson AJ, Kattan MW, Eastham JA, Dotan ZA, Blanco FJ Jr, Lilja H, et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: A proposal for a standardized definition. J Clin Oncol 2006;24:3973-8
6. Yu H, Diamandis EP, Prestigiacomo AF, Stamey TA. Ultrasensitive assay of prostate-specific antigen used for early detection of prostate cancer relapse and estimation of tumor-doubling time after radical prostatectomy. Clin Chem 1995;41:430-4.
7. Hayashi A. Clinical utility of the ultrasensitive prostate specific antigen assay 'IMMULYZE HS-PSA'. J Anal Bio-Sci 2004;27:284-90.
8. Yu H, Diamandis EP, Wong PY, Nam R, Trachtenberg J. Detection of prostate cancer relapse with prostate specific antigen monitoring at levels of 0.001 to 0.1 microG/L. J Urol 1997;157:913-8.
9. Shen S, Lepor H, Yaffee R, Taneja SS. Ultrasensitive serum prostate specific antigen nadir accurately predicts the risk of early relapse after radical prostatectomy. J Urol 2005;173:777-80.
10. Nakamura M, Hasumi H, Miyoshi Y, Sugiura S, Fujinami K, Yao M, et al. Usefulness of ultrasensitive prostate-specific antigen assay for early detection of biochemical failure after radical prostatectomy. Int J Urol 2005;12:1050-4.
11. Japanese Urological Association and the Japanese Society of Pathology, editors. General Rule for Clinical and Pathological Studies on Prostate Cancer. 3rd edn. Tokyo: Kanahara; 2001.
12. Terai A, Matsui Y, Yoshimura K, Arai Y, Dodo Y. Salvage radiotherapy for biochemical recurrence after radical prostatectomy. BJU Int 2005;96:1009-13.
13. Schmid HP, McNeal JE, Stamey TA. Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer 1993;71:2031-40.
14. Chikahira Y, Doi F, Hasegawa E, Hosooka S, Sasagawa N, Matsuda N, et al. Ultrasensitive assay of prostate-specific antigen in radical prostatectomy using Lumipulse 'PSA-N'. J Anal Bio-Sci 2004;27: 279-83.
15. Ornstein DK, Colberg JW, Virgo KS, Chan D, Johnson ET, Oh J, et al. Evaluation and management of men whose radical prostatectomies failed: results of an international survey. Urology 1998;52:1047-54.
16. Cheung R, Kamat AM, de Crevoisier R, Allen PK, Lee AK, Tucker SL, et al. Outcome of salvage radiotherapy for biochemical failure after radical prostatectomy with or without hormonal therapy. Int J Radiat Oncol Biol Phys 2005;63:134-40.
17. Patel A, Dorey F, Franklin, J, deKernion JB. Recurrence patterns after radical retropubic prostatectomy: Clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol 1997;158:1441-5.
18. Shinghal R, Yemoto C, McNeal JE, Brooks JD. Biochemical recurrence without PSA progression characterizes a subset of patients after radical prostatectomy. Prostate-specific antigen. Urology 2003;61: 380-5.
19. Djavan B, Sesterhann I, Hruby S, Susani M, Haitel A, Etemad M, et al. Benign prostatic glands in the surgical margin of radical retropubic prostatectomies: Redefining PSA nadir. J Urol 2000; 163:A624.
20. Haese A, Huland E, Graefen M, Hammerer P, Noldus J, Huland H. Ultrasensitive detection of prostate specific antigen in the followup of 422 patients after radical prostatectomy. J Urol 1999; 161:1206-11.
21. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005;294:433-9.
22. Ward JF, Zincke H, Bergstralh EJ, Slezak JM, Blute ML. Prostate specific antigen doubling time subsequent to radical prostatectomy as a prognosticator of outcome following salvage radiotherapy. J Urol 2004;172:2244-8.
23. Leventis AK, Shariat SF, Kattan MW, Butler EB, Wheeler TM, Slawin KM. Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2001;19:1030-9.
24. Stephenson AJ, Shariat SF, Zelefsky MJ, Kattan MW, Butler EB, Teh BS, et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 2004;291:1325-32.
25. D'Amico AV, Chen MH, Roehl KA, Catalona. WJ. Identifying patients at risk for significant versus clinically insignificant postoperative prostate-specific antigen failure. J Clin Oncol 2005;23:4975-9.